Botulinum toxin type A products: updated warnings regarding risk of iatrogenic botulism
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 15 Jul 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Patients should seek immediate m…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information

Professional
Botulism
This disease is notifiable in the UK. Botulism is caused by botulinum toxin which is a poison produced by the obligate anaerobic bacteria Clostridium botulinum , Clostridium baratii and Clostridium butyricum. The organism is common in the soil and can survive in this environment in the form of a resistant spore. ... There are seven distinct.
by Dr Hayley Willacy, FRCGP

Professional
Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the s....
by Medicines and Healthcare products Regulatory Agency (MHRA)
%3A%20interim%20advice%20on%20risk%20mitigation%20measures%20following%20reports%20of%20deaths%20in%20patients%20while%20taking%20givinostat/og.png)
Professional
Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction
New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s.
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
MOMA Foods is recalling various porridge pots and sachet products because of possible mouse contamination
MOMA Foods is recalling various porridge pots and sachet products because of possible mouse contamination at the manufacturing site. Read the full update from FAS About FSA food safety alerts and recalls The Food Standards Agency (FSA) is responsible for food safety and food hygiene across the UK. Patient.info republishes FSA food safety alerts so.
by Food Standards Agency (FSA)

Professional
FNM Bakery Limited recalls various First National Bakery products because of potential rodent contamination
FNM Bakery Limited is recalling various of their First National Bakery brand products because of potential rodent contamination at the bakery manufacturing site. Read the full update from FAS About FSA food safety alerts and recalls The Food Standards Agency (FSA) is responsible for food safety and food hygiene across the UK. Patient.info.
by Food Standards Agency (FSA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
15 Jul 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- Belzer UW® Cold Storage Solution and Belzer MPS® (UW Machine Perfusion Solution): manufactured by Carnamedica (UKRP: Bridge to Life): Updated advice on the contamination of fluid DSI/2026/006 (update to DSI/2023/005)
- Class 2 Medicines Recall: Bio Products Laboratory Limited, Rabies, Human normal Immunoglobulin 500IU solution for Injection, EL(26)A/18
- Class 2 Medicines Recall: Hameln Pharma Ltd, Clarithromycin 500 mg powder for concentrate for solution for infusion, EL(25)A/53
- NewClass 3 Medicines Recall: Aspire Pharma Limited, Tropicamide 1% Eye Drops, solution in single dose containers 20 x 0.5ml , EL(26)A/47
- Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
- Class 4 Medicines Defect Notification: Fresenius Medical Care Deutschland GmbH, balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, EL(26)A/24
- Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43
- Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
- Field Safety Notices: 02-06 February 2026
- Field Safety Notices: 6 October to 10 October 2025
- Field Safety Notices: 11 to 15 May 2026
- Field Safety Notices: 12 October 2026 to 16 October 2026
- NewField Safety Notices: 19 to 23 October 2026
- Field Safety Notices: 23-27 March 2026
- Field Safety Notices: 26-30 January 2026
- Field Safety Notices: 27 to 31 July 2026
- Field Safety Notices: 27 to 31 October 2025
- MHRA Safety Roundup: November 2025
- Profemur Cobalt Chrome Modular Neck Hip Replacements: Higher than anticipated risk of revision surgery, metal-wear effects and component fracture (DSI/2025/005)
- Radiofrequency (RF) Safety Considerations for Wireless Cardiotocography (CTG) Monitoring Systems (DSI/2026/012)


